文献速递产科母胎医学

隐匿性妊娠期高血压作为不良结局预测因素

Masked pregnancy-associated hypertension as a predictor of adverse outcomes.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-04-23

该回顾性队列研究纳入2016年10月至2020年12月期间在单一医疗系统6家医院分娩的2430例使用Connected Maternity Online Monitoring远程家庭血压监测系统的患者。隐匿性妊娠期高血压定义为临床诊断前远程检测到孕20周后两次收缩压≥140 mmHg或舒张压≥90 mmHg。结果显示隐匿性妊娠期高血压组临床确诊的妊娠期高血压、子痫前期伴严重特征、早产、剖宫产、小于胎龄儿及新生儿重症监护病房入住率均高于正常血压组。

要点

  • 远程家庭血压监测可识别临床检查未发现的隐匿性妊娠期高血压。
  • 隐匿性妊娠期高血压组临床确诊妊娠期高血压66% vs 正常血压组10%(调整OR 17.2)。
  • 该组子痫前期伴严重特征28% vs 2%,早产16% vs 7%,剖宫产38% vs 26%。

核心结论

  • 需更多结局研究,远程血压监测可能成为识别隐匿性高血压相关并发症风险妊娠的重要工具。

研究设计与样本

  • 回顾性队列研究,纳入2016年10月至2020年12月在单一医疗系统6家医院分娩的所有使用Connected Maternity Online Monitoring的患者,共2430例分娩,其中165例符合隐匿性妊娠期高血压标准。
  • 隐匿性妊娠期高血压定义为孕20周后临床诊断前远程检测到两次收缩压≥140 mmHg或舒张压≥90 mmHg。
  • 采用卡方检验和Student t检验比较人口学与结局,逻辑回归按种族、保险和体重指数调整结局。

主要发现

  • 临床确诊的妊娠期高血压在隐匿性妊娠期高血压组66% vs 正常血压组10%(调整OR 17.2;95%CI 11.91-24.81)。
  • 分娩入院时子痫前期伴严重特征:隐匿性妊娠期高血压组28% vs 正常血压组2%(调整OR 23.35;95%CI 14.25-38.26)。
  • 早产:隐匿性妊娠期高血压组16% vs 正常血压组7%(调整OR 2.47;95%CI 1.55-3.94)。
  • 剖宫产:隐匿性妊娠期高血压组38% vs 正常血压组26%(调整OR 1.58;95%CI 1.13-2.23)。
  • 小于胎龄儿:隐匿性妊娠期高血压组11% vs 正常血压组5%(调整OR 2.27;95%CI 1.31-3.94);新生儿重症监护病房入住:8% vs 4%(调整OR 2.20;95%CI 1.18-4.09)。

临床怎么用

  • 原文未据此给出推荐;结论指出需更多结局研究,远程血压监测可能成为识别隐匿性高血压相关并发症风险妊娠的重要工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Masked hypertension has been described in nonpregnant populations as elevated blood pressure in the home setting that is not reproduced on clinical assessment. Patients with masked hypertension have a greater risk of cardiovascular morbidity than patients who have blood pressures within normal range or those with white coat hypertension. OBJECTIVE: This study aimed to determine whether masked pregnancy-associated hypertension detected on Connected Maternity Online Monitoring, a remote home blood pressure monitoring system, is associated with higher rates of hypertensive disorders of pregnancy during delivery admission and maternal and neonatal morbidities. STUDY DESIGN: This was a retrospective cohort study of all patients on Connected Maternity Online Monitoring who delivered at 6 hospitals in a single healthcare system between October 2016 and December 2020. Patients were classified as having either normal blood pressure or masked pregnancy-associated hypertension. Masked pregnancy-associated hypertension was defined as remotely detected systolic blood pressure of ≥140 mm Hg or diastolic blood pressure of ≥90 mm Hg after 20 weeks of gestation on 2 occasions before diagnosis in a clinical setting. The chi-square test and Student t test were used for demographic and outcomes comparisons. Logistic regression was used to adjust outcomes by race, insurance, and body mass index. RESULTS: A total of 2430 deliveries were included in our analysis, including 165 deliveries that met the criteria for masked pregnancy-associated hypertension. Clinically established pregnancy-associated hypertension, defined at the time of delivery, was more common in the masked pregnancy-associated hypertension group than in the normotensive group (66% vs 10%; adjusted odds ratio, 17.2; 95% confidence interval, 11.91-24.81). Patients with masked pregnancy-associated hypertension had higher rates of preeclampsia with severe features on delivery admission than normotensive patients (28% vs 2%; adjusted odds ratio, 23.35; 95% confidence interval, 14.25-38.26). Preterm delivery (16% vs 7%; adjusted odds ratio, 2.47; 95% confidence interval, 1.55-3.94), cesarean delivery(38% vs 26%; adjusted odds ratio, 1.58; 95% confidence interval, 1.13-2.23), small for gestational age (11% vs 5%; adjusted odds ratio, 2.27; 95% confidence interval, 1.31-3.94), and neonatal intensive care unit admission (8% vs 4%; adjusted odds ratio, 2.20; 95% confidence interval, 1.18-4.09) were more common among patients with masked pregnancy-associated hypertension than among normotensive patients. CONCLUSION: With more outcomes research, remote blood pressure monitoring may prove to be an important tool in identifying pregnancies at risk of complications related to masked hypertension.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Mussarat N, Biggio J, Martin J, et al. Masked pregnancy-associated hypertension as a predictor of adverse outcomes. Am J Obstet Gynecol MFM. 2023. PMID: 37098390. doi:10.1016/j.ajogmf.2023.100976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。